Browse by author
Lookup NU author(s): Dr Rebecca PayneORCiD, Alex Nicols, Jess Tyerman, Dr Tom Altmann, Dr Christopher DuncanORCiD, Professor Sophie HambletonORCiD, Professor Muzlifah Haniffa, Dr Brendan PayneORCiD, Dr Jarmila SpegarovaORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2021 The Author(s)Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.
Author(s): Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W, Adele S, Meardon N, Faustini S, Al-Taei S, Moore SC, Tipton T, Hering LM, Angyal A, Brown R, Nicols AR, Gillson N, Dobson SL, Amini A, Supasa P, Cross A, Bridges-Webb A, Reyes LS, Linder A, Sandhar G, Kilby JA, Tyerman JK, Altmann T, Hornsby H, Whitham R, Phillips E, Malone T, Hargreaves A, Shields A, Saei A, Foulkes S, Stafford L, Johnson S, Wootton DG, Conlon CP, Jeffery K, Matthews PC, Frater J, Deeks AS, Pollard AJ, Brown A, Rowland-Jones SL, Mongkolsapaya J, Barnes E, Hopkins S, Hall V, Dold C, Duncan CJA, Richter A, Carroll M, Screaton G, de Silva TI, Turtle L, Klenerman P, Dunachie S, Abuelgasim H, Adland E, Adlou S, Akther HD, Alhussni A, Ali M, Ansari MA, Arancibia-Carcamo CV, Bayley M, Brown H, Chalk J, Chand M, Chawla A, Chinnakannan S, Cutteridge J, de Lara C, Denly L, Diffey B, Dimitriadis S, Drake TM, Donnison T, Dupont M, Eyre D, Fairman A, Gardiner S, Gilbert-Jarmillo J, Goulder P, Hackstein C-P, Hambleton S, Haniffa M, Haworth J, Holmes J, Horner E, Jamsen A, Jones C, Kasanyinga M, Kelly S, Kirk R, Knight ML, Lawrie A, Lee L, Lett L, Lillie K, Lim N, Mehta H, Mentzer AJ, O'Donnell D, Ogbe A, Pace M, Payne BAI, Platt G, Poolan S, Provine N, Ramamurthy N, Robinson N, Romaniuk L, Rongkard P, Sampson OL, Simmons B, Spegarova JS, Stephenson E, Subramaniam K, Thaventhiran J, Thomas S, Travis S, Tucker S, Turton H, Watson A, Watson L, Weeks E, Wilson R, Wood S, Wright R, Xiao H, Zawia AAT
Publication type: Article
Publication status: Published
Journal: Cell
Year: 2021
Volume: 184
Issue: 23
Pages: 5699-5714.e11
Print publication date: 11/11/2021
Online publication date: 16/10/2021
Acceptance date: 12/10/2021
Date deposited: 24/11/2021
ISSN (print): 0092-8674
ISSN (electronic): 1097-4172
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.cell.2021.10.011
DOI: 10.1016/j.cell.2021.10.011
Altmetrics provided by Altmetric
